DETROIT, June 2, 2021 /PRNewswire/ — NAVIGESIA, a personalized medicine software company expands their real-world data tools for clinical neurology and psychology industries, supporting patient management with psychoactive compounds: cannabis, psychedelics, nootropics.
“NAVIGESIA offers a multilingual clinical data platform that remotely engages patients to gather information, enhance workflow, and drive personalized therapeutics across medicine and psychology, for clinical research trials or traditional office encounters,” says CEO/founder, Dr. Ketan Patel. “Think, A.I.-based office assistant that conveniently knows what/when to ask the best questions, and securely transmit this information to trusted stakeholders, cutting time, costs, and frustration.”
The team has deep experience working in neurological and psychological sciences, improving methodologies for meaningful data capture across the entire patient journey. With six years of deployments across diverse healthcare operations (retail, solo practices, and respected US health enterprises), the NAVIGESIA team is expanding their strategy amidst a renaissance in psychedelic and psychoactive compound use.
“Having partnered with the largest private neurology centers in America puts us in an inspired and peer-validated position to refine our suite of brain health tools for this…
